NasdaqGS - Nasdaq Real Time Price USD

Bioventus Inc. (BVS)

Compare

10.04

-0.07

(-0.69%)

At close: 4:00:01 PM EST

10.04

0.00

(0.00%)

After hours: 4:02:00 PM EST

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About Biovent

GlobeNewswire 10 days ago

BVS
-0.69%
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business

Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.

Zacks 14 days ago

BVS
-0.69%
RMD

BSX
Bioventus completes divestiture of its Advanced Rehabilitation business

Bioventus (BVS) announced that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners, a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execution within the Company’s core businesses, while also delivering approximately $20 million of net closing proceeds to enhance liquidity. Published first on TheFl

TipRanks 14 days ago

BVS
-0.69%
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and exe

GlobeNewswire 15 days ago

BVS
-0.69%
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?

Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Zacks 25 days ago

BVS
-0.69%
ADAG
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

BVS
-0.69%
Q3 2024 Bioventus Inc Earnings Call

Q3 2024 Bioventus Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

BVS
-0.69%
Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...

Bioventus Inc (BVS) reports a 15% revenue increase and raises full-year guidance, while addressing market challenges and strategic growth initiatives.

GuruFocus.com 2 months ago

BVS
-0.69%
Bioventus (BVS) Matches Q3 Earnings Estimates

Bioventus (BVS) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

BVS
-0.69%
Bioventus: Q3 Earnings Snapshot

DURHAM, N.C. (AP) — Bioventus Inc. BVS) on Tuesday reported a loss of $4.8 million in its third quarter. On a per-share basis, the Durham, North Carolina-based company said it had a loss of 7 cents.

Associated Press Finance 2 months ago

BVS
-0.69%
Bioventus Reports Third Quarter Financial Results

Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. “We delivered strong financial result

GlobeNewswire 2 months ago

BVS
-0.69%
Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Zacks 2 months ago

BVS
-0.69%
CPRX
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?

Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.

Zacks 2 months ago

BVS
-0.69%
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial

GlobeNewswire 2 months ago

BVS
-0.69%
Bioventus Surges 73% in Three Months: Time to Buy the Stock?

BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.

Zacks 2 months ago

BVS
-0.69%
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?

Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year.

Zacks 2 months ago

CDXC

BVS
-0.69%
Solventum Stock Earns 81 RS Rating

Solventum stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 78 to 81. The healthcare solutions stock debut Mar. 26. IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score.

Investor's Business Daily 3 months ago

SOLV

BVS
-0.69%
BSX
Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Bioventus Inc (BVS) reports a robust 14% organic revenue growth and outlines strategic plans to enhance core business focus.

GuruFocus.com 3 months ago

BVS
-0.69%
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Advanced Rehabilitation business of its subsidiary, Bioness, to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction includes a total cash consideration of $45 million, including $2

GlobeNewswire 3 months ago

BVS
-0.69%
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.

Zacks 3 months ago

ABBV

KRYS

ADMA

Performance Overview

Return	BVS	S&P 500
YTD	-4.74%	+1.52%
1-Year	+106.58%	+25.82%
3-Year	-31.47%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bioventus Inc. (BVS)

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business

Bioventus completes divestiture of its Advanced Rehabilitation business

Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?

Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet

Q3 2024 Bioventus Inc Earnings Call

Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...

Bioventus (BVS) Matches Q3 Earnings Estimates

Bioventus: Q3 Earnings Snapshot

Bioventus Reports Third Quarter Financial Results

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

Bioventus Surges 73% in Three Months: Time to Buy the Stock?

Are Medical Stocks Lagging ChromaDex (CDXC) This Year?

Solventum Stock Earns 81 RS Rating

Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal

Performance Overview